FY2029 Earnings Forecast for Kura Oncology Issued By Wedbush

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Stock analysts at Wedbush issued their FY2029 EPS estimates for shares of Kura Oncology in a research report issued to clients and investors on Thursday, February 6th. Wedbush analyst R. Driscoll expects that the company will post earnings of $2.60 per share for the year. Wedbush has a "Outperform" rating and a $36.00 price objective on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

Several other research analysts have also recently issued reports on the stock. Lifesci Capital upgraded shares of Kura Oncology to a "strong-buy" rating in a report on Tuesday, October 22nd. TD Cowen reaffirmed a "buy" rating on shares of Kura Oncology in a research report on Thursday, November 21st. Bank of America reduced their price target on Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research report on Friday, November 22nd. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They set a "buy" rating and a $27.00 price objective on the stock. Finally, BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $27.13.

Kura Oncology Stock Down 0.8 %

NASDAQ KURA traded down $0.07 on Monday, reaching $8.28. 699,131 shares of the stock traded hands, compared to its average volume of 1,823,542. Kura Oncology has a 12 month low of $6.98 and a 12 month high of $24.17. The company has a market cap of $643.85 million, a price-to-earnings ratio of -3.51 and a beta of 0.78. The company has a fifty day moving average price of $8.58 and a 200-day moving average price of $14.73. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Institutional Investors Weigh In On Kura Oncology

A number of large investors have recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Kura Oncology during the 3rd quarter valued at approximately $25,000. Harbor Advisors LLC purchased a new position in shares of Kura Oncology during the fourth quarter worth $87,000. E Fund Management Co. Ltd. acquired a new position in Kura Oncology during the fourth quarter valued at $90,000. Optimize Financial Inc purchased a new stake in Kura Oncology in the fourth quarter valued at $100,000. Finally, Corient Private Wealth LLC acquired a new stake in Kura Oncology during the 4th quarter worth about $109,000.

Insider Activity at Kura Oncology

In related news, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares of the company's stock, valued at $694,551.11. This represents a 5.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares of the company's stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,255 shares of company stock valued at $100,739 in the last three months. 5.50% of the stock is owned by insiders.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.